Xenpozyme Market Report 2026

Xenpozyme Market Overview

• The Xenpozyme market growth in the historic period has been driven by increased recognition of niemann-pick disease, advancements in recombinant protein production • Market expansion is supported by increasing investments in rare disease pipelines, growing use of personalized medicine approaches • Growth Driver: Growing Prevalence Of Genetic Disorders Drives The Growth Of The Market • North America was the largest region in 2025.

What Is Covered Under Xenpozyme Market?

Xenpozyme is an enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD), including Niemann-Pick disease types A, A/B, and B. It uses recombinant human acid sphingomyelinase (rhASM) to replace the missing enzyme, enabling the breakdown of sphingomyelin, a lipid that accumulates in organs. The main types of indication for xenpozyme are acid sphingomyelinase deficiency (ASMD) with Niemann-Pick disease type A and acid sphingomyelinase deficiency (ASMD) with Niemann-Pick disease type B. Acid sphingomyelinase deficiency (ASMD) with Niemann-Pick disease type A refers to patients with ASMD who also experience the severe neurological and organ dysfunction associated with Niemann-Pick disease type A due to a lack of the enzyme acid sphingomyelinase. It is distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is used by several end users, including adults, geriatrics, and pediatrics.

What Is The Xenpozyme Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investments in rare disease pipelines, growing use of personalized medicine approaches, expansion of newborn screening programs, rising global access to specialty biologics, continued innovation in enzyme stabilization technologies. Major trends in the forecast period include increasing adoption of enzyme replacement therapies, growing focus on rare disease treatment development, expansion of recombinant enzyme manufacturing capabilities, rising emphasis on early diagnosis of lysosomal disorders, improved clinical management of asmd.

Global Xenpozyme Market Segmentation

1) By Indication: Acid Sphingomyelinase Deficiency (ASMD) With Niemann-Pick Disease Type A, Acid Sphingomyelinase Deficiency (ASMD) With Niemann-Pick Disease Type B 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By End-User: Adult, Geriatric, Pediatric

What Are The Drivers Of The Xenpozyme Market?

The growing prevalence of genetic disorders is expected to drive the growth of the xenpozyme market going forward. Genetic disorders refer to conditions caused by abnormalities in an individual's DNA, leading to various health issues. The prevalence of genetic disorders is due to factors such as advancements in genetic testing, greater awareness and diagnosis of rare diseases, and improvements in healthcare. Xenpozyme treats acid sphingomyelinase deficiency (ASMD), a genetic disorder, by supplying the missing acid sphingomyelinase enzyme, crucial for breaking down accumulated sphingomyelin. It helps reduce harmful lipid buildup in cells, improve symptoms, and slow disease progression in ASMD patients. For instance, in October 2024, according to Cystic Fibrosis Trust, a UK-based charity dedicated to supporting people with cystic fibrosis, in 2022, around 11,148 cystic fibrosis (a genetic disorder) patients were registered, and this number grew to 11,318 in 2023, reflecting a 1.5% increase in patient registrations year over year. Therefore, the growing prevalence of genetic disorders is expected to drive the growth of the xenpozyme industry. The increasing demand for personalized medicine is set to propel the growth of the xenpozyme market moving forward. Personalized medicine is a healthcare strategy that customizes treatments according to a person's genetic profile, lifestyle, and unique health needs to achieve better results. Demand for personalized medicine is rising due to advancements in genetic research, increased understanding of individual health profiles, improved diagnostic tools, and the potential for more effective, targeted treatments. Xenpozyme delivers the missing enzyme to break down accumulated substances, providing targeted treatment for MPS I based on the patient's genetic condition. This therapy is specifically developed to address the mutation-driven enzyme deficiency in each patient, offering personalized care. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the increasing demand for personalized medicine is expected to drive the growth of the xenpozyme industry. The expansion of healthcare infrastructure is anticipated to significantly boost the growth of xenpozyme market moving forward. Healthcare infrastructure refers to the physical and organizational structures, facilities, resources, and systems that are necessary for delivering healthcare services to a population. The expansion of healthcare infrastructure is driven by several key factors, including the aging global population, the increase in chronic diseases, and technological advancements. Healthcare infrastructure supports xenpozyme by providing the necessary medical facilities, skilled healthcare professionals, diagnostic tools, and treatment protocols that enable the effective administration of the drug, monitoring of patient progress, and management of potential side effects, ensuring optimal outcomes for patients with chronic hepatitis C. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the expansion of healthcare infrastructure drives the growth of the xenpozyme industry.

Key Players In The Global Xenpozyme Market

Major companies operating in the xenpozyme market are Sanofi S.A.

Regional Insights

North America was the largest region in the xenpozyme market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Xenpozyme Market?

The xenpozyme market consists of sales of reconstitution kits and accessories, administration devices, and complementary diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Xenpozyme Market Report 2026?

The xenpozyme market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the xenpozyme industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.